Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Authors:
- 14 February 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (4) , 1253-1262
Abstract
A core challenge in cancer immunotherapy is to understand the basis for efficacious vaccine responses in human patients. In previous work we identified a melanoma patient who displayed a low-level antivaccine cytolytic T-cell (CTL) response in blood with tumor regression after vaccination with melanoma antigens (MAGE). Using a genetic approach including T-cell receptor β (TCRβ) cDNA libraries, we found very few antivaccine CTLs in regressing metastases. However, a far greater number of TCRβ sequences were found with several of these corresponding to CTL clones specific for nonvaccine tumor antigens, suggesting that antigen spreading was occurring in regressing metastases. In this study, we found another TCR belonging to tumor-specific CTL enriched in regressing metastases and detectable in blood only after vaccination. We used the TCRβ sequence to detect and clone the desired T cells from tumor-infiltrating lymphocytes isolated from the patient. This CD8 clone specifically lysed autologous melanoma cells and displayed HLA-A2 restriction. Its target antigen was identified as the mitochondrial enzyme caseinolytic protease. The target antigen gene was mutated in the tumor, resulting in production of a neoantigen. Melanoma cell lysis by the CTL was increased by IFN-γ treatment due to preferential processing of the antigenic peptide by the immunoproteasome. These results argue that tumor rejection effectors in the patient were indeed CTL responding to nonvaccine tumor-specific antigens, further supporting our hypothesis. Among such antigens, the mutated antigen we found is the only antigen against which no T cells could be detected before vaccination. We propose that antigen spreading of an antitumor T-cell response to truly tumor-specific antigens contributes decisively to tumor regression. Cancer Res; 71(4); 1253–62. ©2011 AACR.Keywords
This publication has 44 references indexed in Scilit:
- A MAGE‐C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapyInternational Journal of Cancer, 2011
- A comprehensive catalogue of somatic mutations from a human cancer genomeNature, 2009
- Results of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patientsCancer, 2009
- Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Frequent expression of the novel cancer testis antigen MAGE‐C2/CT‐10 in hepatocellular carcinomaInternational Journal of Cancer, 2008
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008
- ClpP: A distinctive family of cylindrical energy‐dependent serine proteasesFEBS Letters, 2007
- Mitochondrial localization and oligomeric structure of HClpP, the human homologue of E. coli ClpPJournal of Molecular Biology, 1999
- Human ClpP protease: cDNA sequence, tissue‐specific expression and chromosomal assignment of the geneFEBS Letters, 1995
- Homology in Structural Organization BetweenE. coliClpAP Protease and the Eukaryotic 26 S ProteasomeJournal of Molecular Biology, 1995